Innoviva Inc
NASDAQ:INVA 4:00:00 PM EDT
| Market Cap (Intraday) | 1.26B |
| Current PE | N/A |
| Forward PE | 29.99 |
| 2yr Forward PE | 7.5 |
| 10-Day MA | $20.50 |
| 50-Day MA | $19.63 |
| 200-Day MA | $18.85 |
Innoviva Inc Stock, NASDAQ:INVA
1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010
United States of America
Phone: +1.650.238.9600
Number of Employees: 127
Description
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.